LV10729B - Polynucleotides useful for screening for hepatitis c virus - Google Patents
Polynucleotides useful for screening for hepatitis c virus Download PDFInfo
- Publication number
- LV10729B LV10729B LVP-93-456A LV930456A LV10729B LV 10729 B LV10729 B LV 10729B LV 930456 A LV930456 A LV 930456A LV 10729 B LV10729 B LV 10729B
- Authority
- LV
- Latvia
- Prior art keywords
- hcv
- quot
- sequence
- cdna
- sequences
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 82
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 82
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 82
- 241000711549 Hepacivirus C Species 0.000 title abstract description 517
- 238000012216 screening Methods 0.000 title description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract 3
- 239000002299 complementary DNA Substances 0.000 claims description 231
- 239000000523 sample Substances 0.000 claims description 221
- 239000002773 nucleotide Substances 0.000 claims description 169
- 125000003729 nucleotide group Chemical group 0.000 claims description 165
- 238000000034 method Methods 0.000 claims description 142
- 238000003752 polymerase chain reaction Methods 0.000 claims description 96
- 230000000295 complement effect Effects 0.000 claims description 64
- 150000007523 nucleic acids Chemical class 0.000 claims description 64
- 102000039446 nucleic acids Human genes 0.000 claims description 61
- 108020004707 nucleic acids Proteins 0.000 claims description 61
- 238000009396 hybridization Methods 0.000 claims description 52
- 230000027455 binding Effects 0.000 claims description 27
- 238000009739 binding Methods 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 230000009918 complex formation Effects 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 33
- 208000005176 Hepatitis C Diseases 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 239000013615 primer Substances 0.000 description 223
- 239000002987 primer (paints) Substances 0.000 description 223
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 131
- 150000001413 amino acids Chemical class 0.000 description 78
- 239000000047 product Substances 0.000 description 68
- 235000001014 amino acid Nutrition 0.000 description 56
- 230000003321 amplification Effects 0.000 description 52
- 238000003199 nucleic acid amplification method Methods 0.000 description 52
- 238000003556 assay Methods 0.000 description 50
- 210000002381 plasma Anatomy 0.000 description 50
- 108020004414 DNA Proteins 0.000 description 48
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 39
- 229920001184 polypeptide Polymers 0.000 description 37
- 239000012491 analyte Substances 0.000 description 35
- 241000282577 Pan troglodytes Species 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 34
- 238000002955 isolation Methods 0.000 description 34
- 108010076039 Polyproteins Proteins 0.000 description 31
- 241000710831 Flavivirus Species 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 29
- 208000015181 infectious disease Diseases 0.000 description 27
- 108700026244 Open Reading Frames Proteins 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 108091034117 Oligonucleotide Proteins 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- 241000282579 Pan Species 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 238000011144 upstream manufacturing Methods 0.000 description 18
- 238000012408 PCR amplification Methods 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 108020004635 Complementary DNA Proteins 0.000 description 16
- 102100034349 Integrase Human genes 0.000 description 15
- 238000010367 cloning Methods 0.000 description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 230000008685 targeting Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 108020004705 Codon Proteins 0.000 description 12
- 108010067770 Endopeptidase K Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 239000012472 biological sample Substances 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 11
- 208000006454 hepatitis Diseases 0.000 description 11
- 231100000283 hepatitis Toxicity 0.000 description 11
- 241000710842 Japanese encephalitis virus Species 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 10
- 238000000211 autoradiogram Methods 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 239000002131 composite material Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 108091035707 Consensus sequence Proteins 0.000 description 9
- 108091036078 conserved sequence Proteins 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003155 DNA primer Substances 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 241000710781 Flaviviridae Species 0.000 description 8
- 101710128560 Initiator protein NS1 Proteins 0.000 description 8
- 101710144127 Non-structural protein 1 Proteins 0.000 description 8
- 108091081021 Sense strand Proteins 0.000 description 8
- 208000003152 Yellow Fever Diseases 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000004925 denaturation Methods 0.000 description 8
- 230000036425 denaturation Effects 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000012317 liver biopsy Methods 0.000 description 8
- 230000000379 polymerizing effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 208000001490 Dengue Diseases 0.000 description 7
- 206010012310 Dengue fever Diseases 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000000137 annealing Methods 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 208000025729 dengue disease Diseases 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 241000710886 West Nile virus Species 0.000 description 6
- 241000710772 Yellow fever virus Species 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 239000003999 initiator Substances 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 239000001226 triphosphate Substances 0.000 description 6
- 235000011178 triphosphate Nutrition 0.000 description 6
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 101710172711 Structural protein Proteins 0.000 description 5
- 108010006785 Taq Polymerase Proteins 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 241000710924 Togaviridae Species 0.000 description 4
- -1 antibodies Proteins 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000003161 ribonuclease inhibitor Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229940051021 yellow-fever virus Drugs 0.000 description 4
- 241000713838 Avian myeloblastosis virus Species 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000709721 Hepatovirus A Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 238000009004 PCR Kit Methods 0.000 description 3
- 102000015623 Polynucleotide Adenylyltransferase Human genes 0.000 description 3
- 108010024055 Polynucleotide adenylyltransferase Proteins 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000029570 hepatitis D virus infection Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 230000033458 reproduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 2
- 101710145006 Lysis protein Proteins 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- ODMZDQKUHYGKKN-UHFFFAOYSA-N TCA C Natural products CC(CCCC(C)C1=CCC2(C)OC3=C(CC12)C(=O)C(O)CC3)C(=O)O ODMZDQKUHYGKKN-UHFFFAOYSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- ODPOAESBSUKMHD-UHFFFAOYSA-L 6,7-dihydrodipyrido[1,2-b:1',2'-e]pyrazine-5,8-diium;dibromide Chemical compound [Br-].[Br-].C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 ODPOAESBSUKMHD-UHFFFAOYSA-L 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- AUIJUTGLPVHIRT-FXQIFTODSA-N Arg-Ser-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N AUIJUTGLPVHIRT-FXQIFTODSA-N 0.000 description 1
- 241000182988 Assa Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- PYFIQROSWQERAS-LBPRGKRZSA-N Gly-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(=O)NCC(O)=O)=CNC2=C1 PYFIQROSWQERAS-LBPRGKRZSA-N 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- BERPCVULMUPOER-UHFFFAOYSA-N Quinolinediol Chemical compound C1=CC=C2NC(=O)C(O)=CC2=C1 BERPCVULMUPOER-UHFFFAOYSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 101800000684 Ribonuclease H Proteins 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MCQILDHFZKTBOD-UHFFFAOYSA-N diethoxy-hydroxy-imino-$l^{5}-phosphane Chemical compound CCOP(N)(=O)OCC MCQILDHFZKTBOD-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (19)
- LV 10729 Izgudrojuma formula 1. Oligomērs, kas spēj hibridizēties ar analizējamā parauga polinuk-leotīdu ķēdes HCV secību, atšķiras ar to, ka tas satur HCV saistošu mērķa secību, komplementāru vismaz 4 secīgiem cDNS nukleotīdiem, pie kam HCV cDNS secība atbilst secībām no -340 līdz -320 vai no 8867 līdz 9060 pēc 18. zīm., vai tām komplementārām secībām.
- 2. Oligomērs pēc 1. punkta, kas atšķiras ar to, ka saistošā mērķa secība sastāv no nukleotīdiem, kas ir komplementāri nukleotīdiem, kuri ņemti no šādiem HCV cDNS nukleotīdiem pēc 18. zīm., pie tam nnx-nny apzīmē nukleotīdu secību no nukleotīda x līdz nukleotīdam y: nn.340-nn.330; nn^-nn. 3201" nn.320-nn.310J nn.31Q-nn.3Q0; nn.300-nn.290» n n_29o~nn_28o, nn.2eo~r1n.2701 nn.270 nn.26o; nn.260~nn.250l nn.250-nn.240; nn.240-nn.230; nn.230-nn.220i nn.220~nn.210i nn. 2io*nn.2ooi ηη.2οο~ηη.190; ηη.190-ηη.1β0; nn.180-nn.17o; nn.170-nn.160; nn.16o-nn.15o; ηη.ίδο-ηη.^; nn.14o-nn.13o; nn.^-nn.^oi nn.12o-nn.noi ηη.110-ηη.100; nn.10o~nn.9o; nn.go-nn^o; nn^o-nn.70; nn.70-nn^o; nn^-nn.^,; ηη^-ηη^,; nn^-nn^o; nn.30-nn.20; nn.20~nn.10; nn.ļo-nnļ,· nnrnn10; nn10-nn2oi nn2o~nn3o; ηη^-ηη^; nn4o-nn5o; nnso-nngo; ηη6ο-ηη7ο; ηη7ο-ηη80; nnao-nngo; ηη90-ηη100; nn100-nn110; ηη160*ηη,70; nn22o*nn23oi nn28o~nn29o» nn340-nn35oi ηη4οο~ηη4ΐοί ηη46ο-ηη47ο; nn52o-nn53oi nnsao-nnsgoi nn^o-nneso; nn70o~nn71oi nn76o-nn77oi nn82o~nne3o, nn0go-nn8gO; nn110-nn120 nni70-nn180 nn23o~nn24o nnggo-nngoonn35o~nn3go nn41o-nn42o nn470-nn480 nn53o-nn54o nn59o~nngoo ηη^-ηη^ nn71o-nn72o nn770-nn780 nn^o-nn^o nn12o-nn130 nniao~nn19o nn24o~nn2so nn3oo~nn31o nn36o-nn370 nn42o~nn43o nn48o-nn49o nn54o-nn55o nn6oo-nn6io nn66o~nn67o nn72o-nn73o nn780-nn79o nn89o~nngoo nn^-nneso nn9oo-nngio, nn13o-nn14o; ηη190-ηη2οοί nn25o~nn26oi nn310-nn320; nn37o-nn380; nn43o-nn44o; ηη490-ηη5οο; nnsso-nnseoi nn610-nn620; nn67o-nn68oi nn73o-nn740; nn79o-nn8ooi nn850-nn860; nn^-nn^; nn2oo-nn2io. ηπ26ο~ηη27ο. nn32o~nn33o. nn380-nn390, nn44o-nn45oi nnsoo-nnsio. ηη56ο-ηη570; nn62o~nn63o. nn^-nnego! nn74o~nn75oi nneoo-nneioi nneeo-nn^oi nn150-nn160 nn2io~nn22o nn27o~nn28o nn33o~nn34o nn3go~nn4oo nn45o-nn46o nn51o-nn52o nn570-nn580 nn^-nn^o nn69o~nn7oo nn75o~nn76o nn810-nn82o nn87o~nn880 1 ηη910-ηη92Ο; ηη92ο-ηη930; ηη93ο-ηη94ο.' οο94ο-ηο950; οο95ο-ηο960; ηη960-ηη970; ηη970-ηη980; nogeo-noggo; ηη990-πη10οο.· οο10οο*ηηιοιο! ηηιοιο'ηηιο2ο·' ηη102ο-πη103ο.· ηηιο3ο*ηη1040ί ηη1040-ηηιο5ο; πη1050-ηη1060; ηη1060-ηη1070; nn107o-nn1080; ηο108ο-ηη1090; ηη1090-ηη110ο; ηη110ο"ηηιιιοί nnmo*nnn2o; ηηιΐ2ο*ηηι 130i nn1130-nn1140; nn1140-nnn5^ ηη115ο-ηη1160; ηη1160-ηπ1170; ηη1170-ηη1180; ηη1180-ηπ1190; ηο1190-ηη120ο; οθι200-οο12ι0; ηη121ο-ηη122ο; 00,220-00,230; οο123ο-ηο,240; ηηΐ24ο*ηηΐ25οί nn125o_nni26<> ηη1260-ηη1270; οο1270-ηο1280; ηη1280-ηη1290; ηη1290-ηη13οο: οο13οο* ηη1310; ηη1310-ηη132ο; ηη1320-ηη1330; ηη1330-ηη1340; πη134ο-ηη135ο; nn1350-nn1360; nn136o-nn1370l· ηη1370-ηη1380; πη1380-ηη1390; nn1390-nn1400; ηη1400-ηη1410; ηη1410-οο1420; ηη1420-πη1430; ηη1440-ηη145ο; ηη145ο-ηη1460; πη1460-ηη1470; ηη1470-ηη1480; nni480-nn1490: nn1490*nn1500; nn1SOO"nn1510; ηΓ,1510*ηηΐ52θί ηΠ1520'ηη153θί Πη1530-ηηΐ540; Πη1540-ΠΠ155θί nn15s0'nnl560·' nnl560"nr,157o! nn1570"nnl5a0»" nn1580*nr,1590i nni59o‘nni6ool ηη160ο-ηπ1610; nn1810-nn1620; nn162o-nn1630; nn1630-nn1640; nnļ640-nn1650; nn1650-nn1660; nn1660-nn1670; nn1670-nn1680; nn1680-nn1690; no1690-no,700; ηηΐ700”ηΠ1710Ϊ nnl710’nnl720·’ ηη1720'ηΠ173θΙ OO173q-OO1740! nni740_nnl75o! ηΠ1750" nni76o>‘ οο1760-οο1770; oo1770-no1780; nn1780-nn1790; nn179o-nn1800; nn1800-nn1810,’ nni8io_nni82oī nn1820-nn1830; nn1830-nn1840; nn1840-nn1850; nnl8S0-nn1860; no1860- ηη187θί ηη1870'ηη188θ! nn1880_nn1890>' nn1890_nnl900i nn1900‘nn1910Ī nn1910'nn1920«' nn192o-nn1930; nn1930-nn1940; nn1940-nn1950; nn1950-nn1960; nn1960-nn1970; nn1970-nni98o! nni98o‘nni99o; Οθι990-οο20οο! ηη2οοο’ηη2οιο! ηη2θΐο*ηη2θ2θί 002020-002030; ηη2θ3ο*ηη2θ4οϊ nn2o4o*nn2oso! ηπ2050-ηη2ο6ο! nn2060-nn2o70; nn2070-nn2080; nn2080* ΠΠ2090Ϊ nn2090-nn2100; oo2,qq*oo2i,oi oo2,,o-oo2,2q, oo2,2o-no2,3o> ^^2130-^^2140» nn2140-nn2150; ηη2150·ηη21δ0; οο2,60-οη2,70; nn21 /o~nn2ieo'> nr>2ieo~nn2i9oi oo2190-ΠΠ2200· nn22oo-nn2210; οο^,ο-οο^ο! πη222ο·ηη223ο, oo^o-oo^o, nn^^-nn^so, nn2250'nn2260'< ^n2260‘^^2270i 002270"00228o! ^^2280"^^2290· Οη229ο-Ο023οο> O023oo" ππ23ΐοί nn2310-nn2320; οπ232ο-ππ233ο! πη233ο·ππ2340, πη234ο·πη235ο· on235o*nn23go, ππ236ο-ππ237θί ηη2370-ηη2380; nn238o'nn239oi πη239ο-πη24οο. οη24οο-οο2410, nn24io* ΠΠ2420· ηπ2420-ηη2430; ηη2439-ηη244ο; nn244Q-nn245o! οο245ο-οη246οι nn246Q-nn2470, ηη2470"ηη2480·' ΟΟ2480-ΟΟ2490; ηη2490-ηη2500Ϊ ηη2500'ηη2510Ϊ Ο02510-00252ο! ηη2520" ΠΠ2530· 0^2530-^1^2^01 θη254ο*ΠΠ255θ· ΟΓ)255θ"ηη2560· OO2560"0n2570· ^2S70~n^2S80> οη258ο-οπ259οί ηη2590-ηη2600; οο26οο*οο26ΐο! ηη2610-ηη262ο; ηη2620-ηη263ο; πη2630-ππ2640; ηη2640-ηη265ο; πη285ο'ΠΠ266ο· οη28βο*ηη2670; ηη2670·ηη2680; ηη2680-ηη269ο; ο02690*0η27οο! οη2700-ηη27ιο; πη2710*ηη2720; οη2720-πη2730; οη2730-ηη2740; ηη2740-0 02750· οη2750-ηη276ο; οη2780-ηη2770; οη277ο·οη2780; πο278ο-πο279ο! οη279φ-ηη283ο; Οθ28οο-οπ28ιο·* οη23ΐο'θΠ282θ· οη2829-ππ283ο.’ οπ2330-ππ2840ι· ππ2840-οη2850; πη285ο* οπ2860; οη2860-ηη2870; ηο2370-οο2380; ηη2880-οη2890; οη289ο-οη29οο· οο29οο-οο29ιο! Οθ29ΐο"θο292ο·" οο292ο-ηο293ο; οη293ο-ηο2940; οη2940-ηη295ο,· ηη2959-ηη2980; οο298ο- οο297ο! ηη297ο-ηη298ο; πη2980-ηη299ο! οο299ο-οο3οοο! Οθ3οοο"θθ3οιο! οη3010-ηη3ο2οί ΟΟ3020ΌΠ3030· 003030*0030^! ΟΟ3040-ΟΟ3050· ΟΟ3050ΌΟ306Ο· ΟΟ306Ο-ΟΠ3070· ΟΟ^ο* 00308ο! ΟΟ3080ΌΟ309Ο! ΠΟ3090ΌΟ3100; O031oo*n0311o! Π03ιιο"ΟΠ3ι20· Ο0312ο*00313ο! Ο03ι3ο“003ι4οί 003i4o*003i50· ΟΟ3150ΌΠ3160! Ο03160-00317ο! Ο03170·003ι8ο! 003180- ηθ3190! ηθ319Ο*ΟΟ320θί ΟΟ3200-ΟΠ321 ο! 003210*003220! Οθ3220*ΟΠ323θ! ΟΟ3230-ΟΟ3240; 003240*003250! Π03250"ΟΠ326θ! 003260*00327o! Οθ327ο-Ο0328θ! ΟΟ3280ΌΟ3290! 0032go' ΟΟ3300! 003300-0033,0! 0033,0-003320! 003320*003330! ΟΟ3330ΌΟ3340! ΟΟ3340ΌΠ3350! ΟΟ3350ΌΟ3360! ΟΟ3360ΌΟ3370! ΟΟ3370ΌΟ338Ο» ΟΟ3380ΌΟ3390! 00339θ-0θ34οο! 003^-0034ιο! Ο034ιο-ηθ342ο; n0342o-n0343o! 003430"00344ol 003440-Π03450· 00345θ*ηθ348ο! 003460*00347ο! 00347ο'00348ο! 00348ο-0θ349ο! 00349ο-0035θθ! 0035οο"0θ35ΐο! Οη35ΐο" ΟΠ3620! ΟΟ3520ΌΠ3530! 003530"00354θ! 00354ο"00355θ! ΟΟ3550ΌΟ3560! 003560*On357o! 2 LV 10729 r>n357o-nn358o; ηη358ο-ηη359ο; 003590-003^: ηη^^-ηη^ο; ηη^,ο-ηη^οί ηη^ο* ηη363οΐ ηη3630-ηη364ο; nn^o-nn^soi 003550*003660! 003550-003670: ηθ367ο*οη368ο! nn368o_nn369oi nn3690-nn3700; nn3700-nn3710; nn3710-nn3720; nn372o-nn3730; nn3730-ηη374οί nn374o-nn375o! ππ3750-ηη3760; nn3760-nn3770; nn3770-nn3780; nn3780-nn37g0; nn3790*nn380ol 003500*003510! nn38io'nn3820·” 003520*003830! r,n3830‘nr,3840>' nn3840" nn3850i nn3850‘nn3860i ηη3860'ηΠ387θ! ηη3870'0θ388θί ηη3880*ηη389θί ηη3890*ηΠ3900; nn39oo~nn39io^ nn391o-nn392oI ηη^-ηη^; 003930-003940; 003940*003950! nn3950-nn396o; 003950*003970! on3g7o*nn39eo.‘ nn3g8o*nn3gg0,· η^^-ηη,^οοί O04ooo*on4oio! nn4oto‘nn402ol nn402o*nn403o! 0O4030-0O4040; nn^-nn^o; 004050*004060! 0040^-OO4070; 004070*004080i OO408O-OO4090: 004ogo*n041oo! Οθ410ο-ηθ4ΐιο! 0041ļo'004i20i Οθ4ΐ20"ΟΠ4ΐ3οί ηθ413ο-ηθ414ο; 004T40-004150; Οθ4150-Οθ416ο; n04i60*004l7o! 004170* θη4ιβθ! 004180"00419o! OO4190*004200! ΟΟ4200ΌΠ42ΙΟ: ηθ42ΐο-θη422θ; ΟΟ4220ΌΟ4230: ΟΟ4230ΌΟ424Ο» 0θ4240"0θ425θ! Ο04250*0Ο426θ! 004260*0n427o! ΟΟ4270*Οθ4280» OO428O' Οθ429θ! 004290*ΟΠ430θ! ΟΟ4300ΌΟ4310: 004310*004320! 004320*004330! ΟΟ4330ΌΟ4340: 004340*004350» ΟΟ4350ΌΟ436Ο» 0θ4360*0θ437θ! 004370*004380»* ΟΟ4380ΌΟ439Ο»’ ΟΟ4390" 00φ40θ! 004400*004410» ΟΟ4410ΌΟ442Ο» Ο04420*004430» ΟΟ4430ΌΟ4440» ΟΟ4440ΌΟ445Ο» ΟΠ4450ΌΠ446Ο» ΟΟ4460Ό04470» ΟΟ4470ΌΟ448Ο» 004480*004490» ΟΟ4490ΌΟ450Ο1" ΟΟ4500* 004510! ΟΟ4510ΌΟ4520: 004520*004530»* 004530"0θ454θ! ΟΟ4540ΌΟ455Ο»' ΟΟ4550ΌΟ456Ο: ΟΟ4560ΌΠ457Ο» Οθ4570*Οθ458θ! 004580*0θ459θ! O04590*0n460o! 004600*004610» 004610* 0η462θ! 004620*004630»' 004630*00464o! Οθ4640*ΟΠ465θ! θη4650*ΟΠ466θ! 004660*004670» 004670*004680» ηθ4680*ΟΠ469θ! η04690*0η470θ! 004700*00471o! 0047ΐθ*θη472θ! 004720* 00473θ! ΟΟ4730ΌΟ474Ο' ΟΟ4740ΌΠ4750! 00475θ*ΟΠ476θ! Οη4760'0θ477θ! 004770*0θ478θ! ΟΟ4780ΌΟ4790: ΟΟ4790ΌΟ4800: 004800*004810' ΟΟ4810ΌΟ4820: 004820*004830» 004830* 004840» Οη4840*0θ485θ! ΟΟ4850ΌΟ486Ο1' 004860*004870' Οθ4870*Οθ488θ! Οθ4880*0θ489θ! Οθ489θ*Οθ49θθ! ΟΟ4900ΌΟ4910: ΟΠ49ΐο*Οθ492θ! ΟΠ492θ*Οθ493θ! 004930*004940! OO4g40* ΟΠ4950! 004950*004960! ΟΟ4960ΌΟ4970! ΟΟ4970ΌΟ4980! ΟΟ4980ΌΟ4990: onn5ooo*o0n5oio! 005010*005020! ΟΟ5020ΌΟ5030: On5030*On504o! On5040*OOs050! OO5050*OO5060! 005060* 00δ07θ! 005070*005080' Οθ5θ80*Οθ509θ! ΟΟ5090ΌΟ5100: ΟΟ5100ΌΟ5110» ΟΠ51 io*00si20* 005120*005130! ΟΟ5130ΌΟ5140! 005140*005150! ΟΟ5150ΌΟ5160: 005160-005170; 005ļ7o* OO5180! 005180*0051 go! OOgi90*005200! O05200*0n52io! 005210*005220! ΟΟ5220ΌΠ5230: ΟΟ5230ΌΟ5240! 0θ524θ"00525θ! ΟΟ5250ΌΟ5260: 005260*0n527o; ΟΟ5270ΌΟ5280: OO528O· OO5290: 005290*005300! 005300*005310! 005310*005320! 005320*005330! ΠΟ5330-ΟΟ5340; 005340*005350! ΠΟ5350-ΟΟ5360; 005360*005370! oo5370-nn5380; 005330*005390! O053go* OO5400: 005400*005410! ηθ5410-ηθ542ο; 005420*005430! OO5430-OO5440; 005440*005450! 005450*005480,' ΠΟ5460ΌΟ5470: 005470*005430! On5480*nn5490; 005490*005500! OO5500* on55io! πη55ΐ0-ηθ552ο! Οθ552ο*ηο553ο; ηη553ο-οθ5540; oo5540-on5550; nn5550-on5560; 005560*005570! 005570-0115580: 005530*005590! oOssgo-onseoo! onS6oo-n056io! nn56io* ΟΠ5620: 00582o*00563o! 005330*005640! 005540*005650! 00565o-0 0566o! 00S660*0 0567o! ΟΠ5670ΌΟ5680! Οθ568θ*θη569θ! 005590*005700! 0057οο“ηθ571ο; 005710*005720! 0Π5720* 005730! nO5730-OO5740; ΠΟ5740-ΟΟ5750; 005750*005760! 005760*00577o! 005770*0θ578θ! ΟΟ5780ΌΟ5790! 005790*005800» 005goo*0058lo! Οθ58ΐθ*ΟΠ582θ! 005820*0θ583θ! ΟΟ5830* 005840! 005840*005850» ΟΟ5850ΌΟ5860! ΟΟ5860ΌΟ5870! Οθ5870*Οθ588θ! ΟΟ5880ΌΟ5890! OOsego'Onsgoo! 005goo*005gio! 005910*005920! 00592θ*ΟΠ593θ! 005930*005940! ΟΟ5940* OO595O» ΟΟ5950ΌΠ5960»* ΟΟ5960ΌΠ5970! 005970*005980! 005980*005990! 005990*005000! OOeooo-OOeoio! Οθ60ΐ0*Οθ6020! ΟΟ6020*Οθ6030» 006ο30'0θ6θ4θ! OOg^o'OOgoso» 006050' ΟΟβοβο! 006060*006070» Οθ6θ70*Οη6θ8θ! ΟΟροδΟ'ΟΟβοθο! OOeogo'OOsioo! 006100*006110» Οη6110*00612θ! 006120*ΟΠ6130! OO6i30"OO6i40»‘ 006ΐ4θ*0θ5ΐ5θ! 006ΐ5θ*0θ6ΐ6θ! 00616ο* οη6ΐ70' οο6ΐ7ο"θη6ΐ8ο! on6iao-nn6igo; ηο6ι 90*005200» oo62oo“OOg2io: oOg2ioOo622o: 3 η Π6220'ηη6230' ηη6230'ηη624θ! ηη6240'ΠΠ625θ! ηη6250*ηη626θί ηη6260*Πη627θ! ηη6270" πη628θΙ ηη6280*ηΠ6290> ηη6290*ηη6300> ηη6300*ηΠ631θί ππ6310*ηη6320> η η6320*^6330ί ηη6330'ηη634θί ηη6340*ηη635θ! ηη6350'Πη636θί ηη6360'ηη637θΐ ηη6370*ηη638θ! ηη6380* ΠΓΐ639θ! ^6390^^64001 ^η6400*ΠΠ641θΙ ^6410^^64201 ηη6420'^η6430> ηη6430'ΠΓ16440> ΠΠ6440'ηη645θϊ ^6450^1^6460^ ηη6460*^^6470> ^6470^^64801 ^6480^^6490^ ^^6490' ηΠ6500>’ ηη6500*ηΠ651θ! ηη6510*ηη6520>’ ηΠ6520*ηΠ6530>' ηη6530*ηη6540'' ηη6540*ηη6550>' ηπ6550*ηπ6560· Π^6560·^η6570> nn6570*^rl6580i ηη6580*ηη6590> ^6590^^66001 *^^6600' ηΠ661θ! ηη6610'ηΓΙ6620> ηη6620*ηη663θ! πη6630*ηη664θί ηη6640*ηη6650' ηη6650*ηη666θΐ Πη6660'ηη667θ! ηη6670'ηη668θ! ηη6680*ηη6690> nn6690*nn6700> nn6700'nri671o! ηη6710* ηη672θί ηη6720~ηη673θί ηη6730*ηΠ674θ! ηη6740'ηη675θ! ηη6750*ηη676θ! ηη6760'ηΠ677θ! η^6770*ηη678(> ηΠ6780'Γ'^6790· ^6790*^6800' ηΠ6800*ηη6810> Πη63ΐο'^Π6820· ^Π6820* ΠΠβ83θί ΠΠ683θ·ΠΠ684θΙ ^6840^^6850^ ΠΠβββΟ'^^θθδοΐ ^^6860"^^6870' ^6870^^68801 ΠΠ6880'^^6890» nngggo'nriegooi ^6900^^69101 ^6910^^69201 nng920'nn6g30> ^*^6930' ηη694ο; ηη694ο'ηη695ο· n^6g50"^^6g6o> ηη696ο*ηη697α>' ^6970^^69801 ηη6980-ηη6990; Πη6990"ηη7000· ηη7000'η^7010ι n^7010'flr,7020' η^7020'ηη7030> ^7030^^70401 Γ'η7040' ηη705θ! ηη7050'ηη706θ! ηη7060*ηη7070ι" ηη7070’ηη708θί ηη7080*ηη7090> ηη7090*ηη7100« nn7100'nn711oi ηΠ7110'ηη712θ! ηη7120'ηη713θ! ηη7130*Πη714θί ηη7140’ηη715θί ηη7150* ηη716θ! ηη7160_ηη717θ! ηη7170'ηΠ718θΙ ηη7180*ηη719θ! ηη7190*ηη7200> ηη7200*Πη7210> ^^7210'^^7220« ^^7220*^^7230' ^^230*^7240' ^7240*^7250' ^^7250*^^7260' ^1^7260* Πη727θΐ ^^7270*^^7280' ^7280^^72901 ^7290^^73001 nf^7300*^^7310' ^^7310*^^7320' ηη7320*ηη7330» ηη7330*ηη7340' ηη7340*ηη735θί ηη7350*Πη7360» ηη7360*^η7370» ηΠ7370* ηΓ1738θΐ nn7380*nn7390>‘ nr'7390*nn7400» ηη7400*ηη7410> ηη7410*ηη7420> ηη7420*ηη7430» ^η7430*^^7440» η^7440*ηΓ17450' ηΓ,7450*ηη7460> ^^7460*^^7470' ^7470^^74801 Πη748ο* Γ>Π749οΙ ηη7490*^^7500' ^Π7500*^^751θ! ^7510^^75201 ηη7520*ηΓ1753θ! ηη7530*Γ'^7540' ηη7540'ΠΠ755θί ηΠ7550'ΠΠ756θί ηΠ7560'ηη7570'’ Πη7570*ηη7580> Πη7580*Πη7590· ΠΠ7590* ηη7600> ηη7600"ηη7610' ηη7610"Πη762θί ηη7620*^η7630' ηη7630*ΠΓ,764θ! ηΠ7640*ηη765θί rir17650*nn7660' πη766ο*ππ767οΙ πη767ο*ηη768οΙ ηη7680-ηη7690; ηη7690-ηη770ο! ηη77οο* ηη771θ! ηη7710“ηη772θ! ηη7720*ηη773θ! ηη7730*Πη774θ! ηη7740*ηη775θ! ηη7750*ηΠ776θ! n^776o*rin777o» πη777ο~ηη7780ι nn^so-nn^go; nn7790-nn78ooi ηη78οο*ηη78ΐο> ηη7βιο* ηη782θί ηη7820*^η7830' ^7830~^7870> ηη7870*^η785θ! ηη7850*ηη7860> Πη7860*ηη7870» ^^7870*^^7880» Γ)η7880-ηη7890; nn789o*nn79Qo; πη7900-ηη7910; nn791o_nn7g2o! ^">7920* ηη7930>’ πη7930*ηη7940' nn7940*rln795o! nn7950*nn7960i ηη7960*ηη7970' ηη7970"ηη7980« ηΓ,7980*ηη7990· πη7990'ηΓ,8000· ηη8000*ηη8010>" ηπ8010*ηπ8020> ηη8020*ηη8030>" ^8030* ηη804θΐ ηη8040'ηη8050> ηΓ,8050*ηη8060' ηη8060*ηη8070' ηη8070*ηη8080» ηη8080"ηη8090» ηη8090*ηη8100' Γ'Γ'βΙΟΟ'Γ'^βΙΙΟ· ^η8110*ηη8120' |r,f18120'r,n8130' nneiSO'^f^eHO' n^VuO* ηη8ΐ50; nn8150"nr18160i nfl8i60*nn8170' ηη8170*ηη818θί nn8180"nn8190'' ηη8190*ηη820θΙ ΠΠ82οο"ηη8210> ηη8210*ηη822θ! ΠΠ8220*Πη823θ! ΠΠ823ο*Γΐη324θ! nn8240*nn8250' nn8250* nn8260; nn^eo-nn^o; nn8270-nn8280; nn8280-nn8290,' nn^go-nn^ool πη^οο'Πηββίο! nn8310*^n8320» nn8320'nn8330· nn8330*^^8340> nn8340*nn8350' nf18350*nn8360> nn8360* ηη837θΙ ηη8370"Πη8380· ηη8380*ηΠ8390' ηη8390*ηη840θί nn8400*nn8410» nn8410*nn8420» ηη8420*^Π843θί nn8430*nn8440'" nn8440*nn8450»’ nn8450*nn8460' ηη8460"ηπ8470·" nn8470" ηη848θ! nn8480'nn8490> ηη8490'ηη850θΙ nn8500*nn8510>’ ηπ8510*ηη852θί ηη8520*ηη853θ! nn853o-nn854oJ ηη^ο'πη^ο; ηη8550-ηη8560; nng5go-nn857o; ηη857ο-πη8580; nn8580· nnesgo; nn8590-nn8600; ηη88οο·ηη8610; πη861ο-ηη882ο,' πη8620-ηη863ο! πη8630*^^8640' πη8640*^^8650' ηη8650*|"ΐη8660· ηη8660*^η867θ! ^Γ18670-ηΠ868οΙ Πη8ς8ο-Πη869θ! ^r^go* Πη8700> ηη8700'ηΠ8710' ηη8710*ηΠ8720'’ ^η8720*Γΐη873θΙ ηη8730"ηΠ8740' ηη8740'Γ,η8750» ηη8750*ηΠ876θί ηη8760"ηη878θΙ ηη7770*ηη878θ! ηη8780'ηΠ879θ! ΠΠ8790*ΠΠ8800' ηη7800* ηη881θ! ηπ8810"ηη882θί ηπ8820*ηη883θ! ηη8830*ηη887θ! ηη8870*ΠΠ885θ! ηη8850*ηη8860' 4 LV 10729 nn8860"nn8870· ηΠ8β70'Γ*^8880» Π^βββΟ'Γ'^ββθΟ· ηηβ890·η·"·8900> ^^8900*^^8910> ^8910" πη892οί πηβ92ο_,ιη893ο· πθθ93ο"ηη897ο« ηη897ο·ηη895ο; ηη8950-ηη8960; ηη898ο-ηη897οΐ nn8970"nn8980· ηη8980*η^8990> nn8990‘^^9000· nn9000"n^9010> ΠΠ9οιο"Πη9020» n^9020" ΠΠ9030; nn903o*nngo4o* ππ9040_πη9050» nngoso'nrig^.
- 3. Oligomērs pēc 1. punkta, kas atšķiras ar to, ka mērķa secība veidota no secības, kas ir komplementāra vismaz 8 nukleotīdu secībai konservatīvajā HCV nukleotīdu secībā HCV RNS.
- 4. Oligomērs pēc 3. punkta, kas atšķiras ar to, ka konservatīvā secība atrodas nukleotīdu secībā ap 200. vietu no 5’ gala 18. zīm.
- 5. Oligomērs pēc 3. punkta, kas atšķiras ar to, ka konservatīvā secība atrodas nukleotīdu secībā no apmēram 4000. vietas līdz 5000. vietai 18. zīm.
- 6. Oligomērs pēc 3. punkta, kas atšķiras ar to, ka konservatīvā secība atrodas nukleotīdu secībā no apmēram 8000. vietai līdz 9040. vietai 18. zīm.
- 7. Oligomērs pēc 3. punkta, kas atšķiras ar to, ka konservatīvā secība atrodas nukleotīdu secībā no apmēram -318. vietas līdz apmēram 174. vietai 18. zīm.
- 8. Oligomērs pēc 3. punkta, kas atšķiras ar to, ka konservatīvā secība atrodas nukleotīdu secībā no apmēram 4056. vietas līdz 4448. vietai.
- 9. Oligomērs pēc 3. punkta, kas atšķiras ar to, ka konservatīvā secība atrodas nukleotīdu secībā no apmēram 44378. vietas līdz 4902. vietai.
- 10. Oligomērs pēc 3. punkta, kas atšķiras ar to, ka konservatīvā secība atrodas nukleotīdu secībā no apmēram 4042. vietas līdz 4059. vietai.
- 11. Oligomērs pēc 3. punkta, kas atšķiras ar to, ka konservatīvā secība atrodas nukleotīdu secībā no apmēram 4456. vietas līdz 4470. vietai.
- 12. Oligomērs pēc 3. punkta, kas atšķiras ar to, ka konservatīvā secība atrodas nukleotīdu secībā no apmēram 8209. vietas līdz 8217. vietai.
- 13. Oligomērs pēc jebkura no 3.-12. punktiem, kas atšķiras ar to, ka tas ir saistīšanās zonde.
- 14. Oligomērs pēc jebkura no 3.-12. punktiem, kas atšķiras ar to, ka tas ir iezīmēšanas zonde.
- 15. Oligomērs pēc jebkura no 3.-12. punktiem, kas atšķiras ar to, ka tas ir praimers.
- 16. Paņēmiens HCV secības identificēšanai paraugā, kurā var sagaidīt HCV secības esamību, pie kam HCV secība satur izvēlētu mērķa secību, kas atšķiras ar to, ka: 5 (a) sagatavo oligomēru, kas spēj hibridizēties ar HCV secību parauga polinukleotīdu ķēdē, pie kam oligomērs satur HCV saistošo mērķa secību atbistoši jebkuram no iepriekšējiem punktiem; (b) inkubē parauga ķēdi ar posmā (a) minēto oligomēru, jaujot veidoties specifiskiem hibridizācijas dupleksiem starp saistošo mērķa secību un mērķa secību; un (c) nosaka hibrīdus, kas izveidojušies starp oligomēru un mērķa secību, ja paraugs tādu ir saturējis.
- 17. Paņēmiens pēc 16. punkta, kas atšķiras ar to, ka papildus paredz to, ka: (a) pagatavo oligomēru komplektu, kuri kalpo par praimeriem polimerāzes ķēdes reakcijai un kuri atrodas blakus mērķa rajonam; (b) pavairo mērķa rajonu ar polimerāzes ķēdes reakciju.
- 18. Reaģents HCV mērķa secības identificēšanai parauga ķēdē, kas satur oligomēru pēc jebkura no 1.-15. punktiem piemērotā iesaiņojumā.
- 19. Paņēmiens no HCV brīvu asiņu sagatavošanai, kas atšķiras ar to, ka tas ietver (a) nukleīnskābju parauga sagatavošanu no asiņu krājuma, kurā var sagaidīt HCV mērķa secību; (b) oligomēra pagatavošanu, kurš spēj hibridizēties ar HCV secību parauga polinukieotīda ķēdē, ja tāda secība paraugā atrodama, pie kam oligomērs satur HCV mērķa saistīšanas secību pēc jebkura no 3.-15. punktiem; (c) posmos (a) un (b) sagatavoto sastāvdaļu savienošanu tādos apstākļos, kas ļauj veidoties polinukleotīdu dupleksam starp mērķa saistīšanas secību un mērķa secību, ja tāda ir paraugā; (d) dupleksa detektēšanu, ja tāds izveidojies posmā (c); un (e) asiņu krājuma saglabāšanu, ja posmā (d) nedetektē kompleksa veidošanos. 6
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35596189A | 1989-05-18 | 1989-05-18 | |
| US45663789A | 1989-12-21 | 1989-12-21 | |
| US50543590A | 1990-04-04 | 1990-04-04 | |
| PCT/US1990/002853 WO1990014436A1 (en) | 1989-05-18 | 1990-05-18 | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10729A LV10729A (lv) | 1995-06-20 |
| LV10729B true LV10729B (en) | 1995-12-20 |
Family
ID=27408242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-93-456A LV10729B (en) | 1989-05-18 | 1993-06-01 | Polynucleotides useful for screening for hepatitis c virus |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0398748B1 (lv) |
| JP (3) | JP2656996B2 (lv) |
| AT (1) | ATE211772T1 (lv) |
| AU (1) | AU638719B2 (lv) |
| BG (1) | BG60348B2 (lv) |
| CA (1) | CA2017157C (lv) |
| DE (1) | DE69033891T2 (lv) |
| DK (1) | DK0398748T3 (lv) |
| ES (1) | ES2166749T3 (lv) |
| FI (1) | FI105279B (lv) |
| GE (1) | GEP20002164B (lv) |
| HU (1) | HUT59964A (lv) |
| LV (1) | LV10729B (lv) |
| MC (1) | MC2188A1 (lv) |
| NO (1) | NO303503B1 (lv) |
| RO (1) | RO113059B1 (lv) |
| WO (1) | WO1990014436A1 (lv) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6489246A (en) * | 1987-09-30 | 1989-04-03 | Sony Corp | Fixing method for color sorting mechanism of color cathode-ray tube |
| US6171782B1 (en) | 1987-11-18 | 2001-01-09 | Chiron Corporation | Antibody compositions to HCV and uses thereof |
| US5714596A (en) * | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
| US6861212B1 (en) | 1987-11-18 | 2005-03-01 | Chiron Corporation | NANBV diagnostics and vaccines |
| US5712088A (en) * | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
| US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
| US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
| US7166287B1 (en) | 1989-12-18 | 2007-01-23 | Glaxo Wellcome Inc. | Viral agent |
| NZ236491A (en) | 1989-12-18 | 1993-10-26 | Wellcome Found | Post-transfusional non-a non-b hepatitis viral polypeptides, dna, antigenic polypeptides and antibodies to the polypeptides |
| EP0461863A1 (en) * | 1990-06-12 | 1991-12-18 | Immuno Japan Inc. | Oligonucleotide primers, and their application for high-fidelity detection of non-A, non-B hepatitis virus |
| US5747339A (en) | 1990-06-25 | 1998-05-05 | Research Foundation For Microbial Diseases Of Osaka | Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide |
| ES2069298T3 (es) * | 1990-06-30 | 1995-05-01 | Akzo Nobel Nv | Secuencias no-a no-b. |
| DE69125066T2 (de) * | 1990-07-11 | 1997-09-25 | Shionogi Seiyaku K K Trading U | cDNS-Sequenz und Detektion des Hepatitis C-Virus |
| WO1992001714A1 (en) * | 1990-07-24 | 1992-02-06 | Yamanouchi Pharmaceutical Co., Ltd. | Non-a non-b hepatitis virus antigen |
| CA2089080C (en) * | 1990-08-10 | 2007-04-03 | Michael Houghton | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus |
| KR920703640A (ko) * | 1990-11-29 | 1992-12-18 | 테루카츄 아리마 | 비a비b형 간염 바이러스 항원 단백질 |
| WO1992012992A2 (en) * | 1991-01-14 | 1992-08-06 | James N. Gamble Institute Of Medical Research | Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods |
| ES2066547T3 (es) * | 1991-03-01 | 1995-03-01 | Akzo Nobel Nv | Peptidos, inmunoquimicamente reactivos con anticuerpos dirigidos contra virus de hepatitis no-a, no-b. |
| US5574132A (en) * | 1991-04-05 | 1996-11-12 | Biochem Immunosystems Inc. | Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV) |
| EP0510952A1 (en) * | 1991-04-26 | 1992-10-28 | Immuno Japan Inc. | Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus |
| FR2677372B1 (fr) * | 1991-06-06 | 1994-11-10 | Pasteur Institut | Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques. |
| IT1249684B (it) * | 1991-07-19 | 1995-03-09 | Sorin Biomedica Spa | Epitopi della proteina env del virus dell'epatite c. |
| ES2198514T3 (es) * | 1991-08-27 | 2004-02-01 | F. Hoffmann-La Roche Ag | Cebadores y sondas para la deteccion de la hepatitis c. |
| WO1993005181A1 (en) * | 1991-09-12 | 1993-03-18 | Cedars-Sinai Medical Center | Direct detection of hepatitis c virus rna |
| DE69232859T2 (de) * | 1991-09-13 | 2003-04-10 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden |
| AU3063992A (en) * | 1991-11-07 | 1993-06-07 | Dade International Inc. | Epitope mapping ot the c33c region of hcv |
| ES2065863T3 (es) | 1991-11-21 | 2003-09-01 | Common Services Agency | Analisis para la deteccion de virus de la hepatitis c. |
| GB9204274D0 (en) * | 1992-02-28 | 1992-04-08 | Wellcome Found | Novel peptides |
| US5866139A (en) * | 1992-06-04 | 1999-02-02 | Institut Pasteur | Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications |
| US5922857A (en) * | 1992-09-28 | 1999-07-13 | Chiron Corporation | Methods and compositions for controlling translation of HCV proteins |
| JPH06153961A (ja) * | 1992-11-27 | 1994-06-03 | Imuno Japan:Kk | Ｃ型肝炎ウイルス部分遺伝子、ならびにｃ型肝炎ウイルス遺 伝子の高感度検出法 |
| CA2162557C (en) | 1993-05-12 | 2004-09-28 | Amy J. Weiner | Conserved motif of hepatitis c virus e2/ns1 region |
| WO1996004301A2 (en) * | 1994-07-29 | 1996-02-15 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| CA2195312A1 (en) | 1994-07-29 | 1996-02-15 | Mark Selby | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| US5837442A (en) | 1995-11-29 | 1998-11-17 | Roche Molecular Systems, Inc. | Oligonucleotide primers for amplifying HCV nucleic acid |
| ATE437951T1 (de) | 1997-05-06 | 2009-08-15 | Novartis Vaccines & Diagnostic | Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 |
| DE19832050C2 (de) * | 1998-07-16 | 2002-10-10 | Biotest Pharma Gmbh | Verfahren zum Nachweis von Hepatitis B- bzw. Hepatitis C-Virusgenomen in Plasmaproben und spezifische Primer |
| AU4673099A (en) | 1999-02-26 | 2000-09-14 | Chiron Corporation | Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
| US8206749B1 (en) | 1999-02-26 | 2012-06-26 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
| US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
| MXPA02012424A (es) * | 2000-06-15 | 2003-04-25 | Chiron Corp | Ensayo de combinacion de antigenos/anticuerpos para el virus de hepatitis c. |
| US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US6858590B2 (en) | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| AU9215101A (en) | 2000-08-17 | 2002-02-25 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US6586584B2 (en) | 2001-01-29 | 2003-07-01 | Becton, Dickinson And Company | Sequences and methods for detection of Hepatitis C virus |
| ES2345876T3 (es) | 2001-05-31 | 2010-10-05 | Novartis Vaccines And Diagnostics, Inc. | Particulas de replicones de alfavirus quimericos. |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| CA2476626A1 (en) | 2002-02-20 | 2003-08-28 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
| US7598421B2 (en) | 2002-05-08 | 2009-10-06 | Ucl Biomedica Plc | Materials for the delivery of biologically-active material to cells |
| EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| US7695725B2 (en) | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
| JP4545151B2 (ja) | 2003-02-06 | 2010-09-15 | シーラス コーポレイション | 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法 |
| KR101173871B1 (ko) | 2003-02-06 | 2012-08-16 | 앤저 테라퓨틱스 인코퍼레이티드 | 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법 |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| US20090317420A1 (en) | 2004-07-29 | 2009-12-24 | Chiron Corporation | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| JP5070055B2 (ja) | 2004-08-27 | 2012-11-07 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 改変タンパク分解性切断部位を有するｈｃｖ多エピトープ融合抗原およびその使用 |
| US7968697B2 (en) | 2005-05-25 | 2011-06-28 | Chrontech Pharma Ab | Hepatitis C virus non-structural NS3/4A fusion gene |
| EP2121991A2 (en) * | 2006-10-20 | 2009-11-25 | Innogenetics N.V. | Methodology for analysis of sequence variations within the hcv ns3/4a genomic region |
| EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
| US20090214593A1 (en) | 2007-08-16 | 2009-08-27 | Tripep Ab | Immunogen platform |
| US8815253B2 (en) | 2007-12-07 | 2014-08-26 | Novartis Ag | Compositions for inducing immune responses |
| CA2724649A1 (en) | 2008-05-19 | 2009-11-26 | Anza Therapeutics, Inc. | Compositions comprising prfa* mutant listeria and methods of use thereof |
| KR20120022760A (ko) | 2009-03-09 | 2012-03-12 | 윌리엄 헨리 | 담체로서 시그널 펩티드를 가지는 박테리아 독소를 포함하는 햅텐-담체 접합체와 면역원성 조성물에 있어서 이의 용도 |
| FI122954B (fi) | 2011-01-31 | 2012-09-14 | Teknoware Oy | LED-putkilamppu ja valaisinjärjestely |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| HU216017B (hu) * | 1987-11-18 | 1999-04-28 | Chiron Corp. | Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt |
| US5191064A (en) * | 1988-09-30 | 1993-03-02 | The Research Foundation For Microbial Diseases (Osaka University) | Non-a, non-b hepatitis virus antigen peptide |
| HU225068B1 (en) * | 1989-03-17 | 2006-05-29 | Chiron Corp | Process for producing diagnostics and vaccine of nanbh |
| AU638304B2 (en) * | 1989-12-22 | 1993-06-24 | Abbott Laboratories | Hepatitis c assay |
| EP0527786A1 (en) * | 1990-04-03 | 1993-02-24 | Southwest Foundation For Biomedical Research | Purified hcv and hcv proteins and peptides |
-
1990
- 1990-05-18 RO RO149205A patent/RO113059B1/ro unknown
- 1990-05-18 ES ES90305421T patent/ES2166749T3/es not_active Expired - Lifetime
- 1990-05-18 DK DK90305421T patent/DK0398748T3/da active
- 1990-05-18 WO PCT/US1990/002853 patent/WO1990014436A1/en active IP Right Grant
- 1990-05-18 AU AU58123/90A patent/AU638719B2/en not_active Expired
- 1990-05-18 GE GE1876A patent/GEP20002164B/en unknown
- 1990-05-18 MC MC@@@@@@@@@@@@D patent/MC2188A1/xx unknown
- 1990-05-18 CA CA002017157A patent/CA2017157C/en not_active Expired - Lifetime
- 1990-05-18 EP EP90305421A patent/EP0398748B1/en not_active Expired - Lifetime
- 1990-05-18 HU HU904754A patent/HUT59964A/hu unknown
- 1990-05-18 AT AT90305421T patent/ATE211772T1/de not_active IP Right Cessation
- 1990-05-18 DE DE69033891T patent/DE69033891T2/de not_active Expired - Lifetime
- 1990-05-18 JP JP2508534A patent/JP2656996B2/ja not_active Expired - Lifetime
-
1991
- 1991-11-18 FI FI915443A patent/FI105279B/fi active
- 1991-11-18 BG BG095495A patent/BG60348B2/bg unknown
- 1991-11-18 NO NO914517A patent/NO303503B1/no not_active IP Right Cessation
-
1993
- 1993-06-01 LV LVP-93-456A patent/LV10729B/en unknown
-
1996
- 1996-10-30 JP JP30570796A patent/JP3701754B2/ja not_active Expired - Lifetime
-
1997
- 1997-05-19 JP JP14598597A patent/JP3698520B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH1089A (ja) | 1998-01-06 |
| LV10729A (lv) | 1995-06-20 |
| EP0398748A3 (en) | 1991-10-23 |
| NO914517L (no) | 1992-01-16 |
| FI105279B (fi) | 2000-07-14 |
| CA2017157A1 (en) | 1990-11-18 |
| RO113059B1 (ro) | 1998-03-30 |
| EP0398748A2 (en) | 1990-11-22 |
| DK0398748T3 (da) | 2002-03-18 |
| ES2166749T3 (es) | 2002-05-01 |
| JP3701754B2 (ja) | 2005-10-05 |
| AU638719B2 (en) | 1993-07-08 |
| HU904754D0 (en) | 1992-01-28 |
| AU5812390A (en) | 1990-12-18 |
| MC2188A1 (fr) | 1992-09-16 |
| EP0398748B1 (en) | 2002-01-09 |
| JP2656996B2 (ja) | 1997-09-24 |
| NO303503B1 (no) | 1998-07-20 |
| ATE211772T1 (de) | 2002-01-15 |
| HUT59964A (en) | 1992-07-28 |
| GEP20002164B (en) | 2000-07-10 |
| JPH05500155A (ja) | 1993-01-21 |
| JPH10113176A (ja) | 1998-05-06 |
| FI915443A0 (fi) | 1991-11-18 |
| DE69033891T2 (de) | 2002-08-29 |
| WO1990014436A1 (en) | 1990-11-29 |
| NO914517D0 (no) | 1991-11-18 |
| BG60348B2 (bg) | 1994-09-30 |
| DE69033891D1 (de) | 2002-02-21 |
| CA2017157C (en) | 2003-07-29 |
| JP3698520B2 (ja) | 2005-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2017157C (en) | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus | |
| US5714596A (en) | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus | |
| US5863719A (en) | Methods for detecting hepatitis C virus using polynucleotides specific for same | |
| EP0543924B1 (en) | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus | |
| EP0388232B9 (en) | NANBV diagnostics and vaccines | |
| US6495670B1 (en) | Process for typing of HCV isolates | |
| EP0633320A1 (en) | Oligonucleotides of HCV, primers ND probes therefrom, method of determining HCV genotypes and method of detecting HVC in samples | |
| RU2145635C1 (ru) | Олигомер (варианты), способ обнаружения последовательности hcv (варианты), набор для обнаружения, способ получения крови | |
| US20040101820A1 (en) | Polynucleotide probe and primer originating in hepatitis e virus of japanese, chips having the same, kits having the same and method of detecting hepatits e virus using the same | |
| PT94081B (pt) | Diagnosticos para o nambv: polinucleotidos uteis na deteccao do virus da hepatite c | |
| Wei et al. | Genetic variability and characterization of non-structural region 5 of hepatitis C virus genome from Chinese patients | |
| WOLFE et al. | J.-C. RYFF with the Viral Hepatitis Study Group4 | |
| IE84606B1 (en) | NANBV diagnostics and vaccines | |
| CA2483289A1 (en) | Hepatitis c diagnostics and vaccines |